Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19.
Saved in:
| Title: | Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19. |
|---|---|
| Authors: | Shivram H; Genentech, South San Francisco, CA 94080, USA., Hackney JA; Genentech, South San Francisco, CA 94080, USA., Rosenberger CM; Genentech, South San Francisco, CA 94080, USA., Teterina A; Hoffmann-La Roche Ltd, Mississauga, ON L5N 5M8, Canada., Qamra A; Hoffmann-La Roche Ltd, Mississauga, ON L5N 5M8, Canada., Onabajo O; Genentech, South San Francisco, CA 94080, USA., McBride J; Genentech, South San Francisco, CA 94080, USA., Cai F; Genentech, South San Francisco, CA 94080, USA., Bao M; Genentech, South San Francisco, CA 94080, USA., Tsai L; Genentech, South San Francisco, CA 94080, USA., Regev A; Genentech, South San Francisco, CA 94080, USA., Rosas IO; Baylor College of Medicine, Houston, TX 77030, USA., Bauer RN; Genentech, South San Francisco, CA 94080, USA. |
| Source: | IScience [iScience] 2023 Aug 11; Vol. 26 (9), pp. 107597. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2589-0042 |
|---|---|
| DOI: | 10.1016/j.isci.2023.107597 |
